The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study
The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study
复制标题
DOI：
10.1016/j.ygyno.2013.11.016
复制
发表时间：
2014-03-01
影响因子：
4.7
通讯作者：
Gershenson, David M.
中科院分区：
文献类型：
--
作者：
Fader, Amanda Nickles;Java, James;Gershenson, David M.
目标。该研究的目的是确定血清CA-125水平在III期研究中1级浆液性卵巢癌（SOC）患者的预后意义。卡铂/紫杉醇治疗晚期上皮性卵巢癌妇女与三联或序贯双联方案的III期研究的辅助分析1级SOC被用作低级别浆液性癌的替代物。在3686例入组患者中，184例（5%）为1级疾病，CA-125水平可用。对于1级SOC患者，中位年龄为56.5岁；87.3%为III期。中位随访时间为102个月，化疗前CA-125治疗组差异无统计学意义（P = 0.91）。1级SOC患者预处理CA-125的中位数（119.1）低于2-3级SOC患者（246.7;P < 0.001）。在1级患者中，预处理CA-125对预后没有影响。然而，CA-125水平在第1、2或3周期后正常化的患者，与那些在4个周期后从未正常化或正常化的患者相比，疾病进展的可能性降低了60-64%
Objectives. The study objective was to determine the prognostic significance of serum CA-125 levels in patients with grade 1 serous ovarian carcinoma (SOC) enrolled in a Phase III study.Methods. An ancillary analysis of a phase III study of women with advanced epithelial ovarian cancer treated with carboplatin/paclitaxel versus triplet or sequential doublet regimens. Grade 1 SOC was used as a surrogate for low-grade serous carcinoma.Results. Among 3686 enrolled patients, 184 (5%) had grade 1 disease and CA-125 levels available. For those with grade 1 SOC, the median patient age was 56.5; 87.3% had Stage III disease. Median follow-up was 102 months and there was no difference in pre-chemotherapy CA-125 by treatment arm (P = 0.91). Median pretreatment CA-125 for those with grade 1 SOC was lower (119.1) than for patients with grade 2-3 SOC (246.7; P < 0.001). In those with grade 1, pretreatment CA-125 was not prognostic of outcome. However, patients with CA-125 levels that normalized after cycle 1, 2 or 3 were 60-64% less likely to experience disease progression as compared to those who never normalized or normalized after 4 cycles (P